1.
Chimalakonda A, Burke J, Cheng L, Catlett I, Patel A, Shen J, Girgis I, Banerjee S, Throup J. Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors. J of Skin [Internet]. 2020Oct.27 [cited 2022May18];4(6):s108. Available from: https://www.jofskin.org/index.php/skin/article/view/1081